| Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in … M Ronot, M Bouattour, J Wassermann, O Bruno, C Dreyer, B Larroque, ... The oncologist 19 (4), 394-402, 2014 | 172 | 2014 |
| Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide … A Lievre, A Turpin, I Ray-Coquard, K Le Malicot, J Thariat, G Ahle, ... European Journal of Cancer 141, 62-81, 2020 | 146 | 2020 |
| Redifferentiation of radioiodine-refractory thyroid cancers C Buffet, J Wassermann, F Hecht, L Leenhardt, C Dupuy, L Groussin, ... Endocrine-Related Cancer 27 (5), R113-R132, 2020 | 71 | 2020 |
| Cardiac arrhythmia considerations of hormone cancer therapies M Barber, LS Nguyen, J Wassermann, JP Spano, C Funck-Brentano, ... Cardiovascular Research 115 (5), 878-894, 2019 | 62 | 2019 |
| Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study EG Kaboré, C Guenancia, I Vaz-Luis, A Di Meglio, B Pistilli, C Coutant, ... PLoS medicine 16 (12), e1002989, 2019 | 60 | 2019 |
| Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series MJ Rodrigues, J Peron, JS Frenel, YA Vano, J Wassermann, M Debled, ... Annals of oncology 24 (4), 916-924, 2013 | 57 | 2013 |
| Trastuzumab treatment in T1ab, node-negative, human epidermal growth factor receptor 2–overexpressing breast carcinomas MJ Rodrigues, J Wassermann, L Albiges, E Brain, S Delaloge, D Stevens, ... Journal of Clinical Oncology 28 (28), e541-e542, 2010 | 52 | 2010 |
| Outcomes and prognostic factors in radioiodine refractory differentiated thyroid carcinomas J Wassermann, MO Bernier, JP Spano, C Lepoutre-Lussey, C Buffet, ... The Oncologist 21 (1), 50-58, 2016 | 51 | 2016 |
| Nonadherent behaviors among young women on adjuvant endocrine therapy for breast cancer J Wassermann, SI Gelber, SM Rosenberg, KJ Ruddy, RM Tamimi, ... Cancer 125 (18), 3266-3274, 2019 | 36 | 2019 |
| Effect of buparlisib, a pan-class I PI3K inhibitor, in refractory follicular and poorly differentiated thyroid cancer F Borson-Chazot, E Dantony, F Illouz, J Lopez, P Niccoli, J Wassermann, ... Thyroid 28 (9), 1174-1179, 2018 | 29 | 2018 |
| Treatment of node-negative infra-centimetric HER2+ invasive breast carcinomas: a joint AERIO/REMAGUS study MJ Rodrigues, J Wassermann, L Albiges-Sauvin, D Stevens, E Brain, ... Journal of Clinical Oncology 27 (15_suppl), 517-517, 2009 | 28 | 2009 |
| Utilisation des médecines alternatives et complémentaires par les patients en cancérologie: résultats de l’étude MAC-AERIO M Rodrigues, J Wassermann, P Barthélémy, S Rajpar, T Khoa, ... Eurocancer 2010, 95-96, 2010 | 25 | 2010 |
| Heterogeneity of hepatocellular carcinoma on imaging J Rimola Seminars in Liver Disease 40 (01), 061-069, 2020 | 17 | 2020 |
| Clinical pharmacology of anti-angiogenic drugs in oncology P Gougis, J Wassermann, JP Spano, N Keynan, C Funck-Brentano, ... Critical Reviews in Oncology/Hematology 119, 75-93, 2017 | 17 | 2017 |
| Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: biomarkers and functional imaging M Bouattour, A Payancé, J Wassermann World journal of hepatology 7 (20), 2245, 2015 | 16 | 2015 |
| Body weight and return to work among survivors of early-stage breast cancer A Di Meglio, G Menvielle, A Dumas, A Gbenou, S Pinto, T Bovagnet, ... ESMO open 5 (6), e000908, 2020 | 14 | 2020 |
| Treatment decisions and adherence to adjuvant endocrine therapy in breast cancer J Wassermann, SM Rosenberg Current Breast Cancer Reports 9, 100-110, 2017 | 14 | 2017 |
| Vitamine D et cancers M Espié, J Wassermann, E de Kermadec, M Lalloum, F Coussy La Presse Médicale 42 (10), 1405-1411, 2013 | 13 | 2013 |
| Impact of age on survival in radioiodine refractory differentiated thyroid cancer patients C Saïe, J Wassermann, E Mathy, N Chereau, L Leenhardt, ... European Journal of Endocrinology 184 (5), 667-676, 2021 | 12 | 2021 |
| Intermittent versus continuous administration of pazopanib in progressive radioiodine refractory thyroid carcinoma: Final results of the randomised, multicenter, open-label … C de la Fouchardière, Y Godbert, C Dalban, F Illouz, J Wassermann, ... European Journal of Cancer 157, 153-164, 2021 | 11 | 2021 |
